Arbor Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Atlanta GA United States (2006)
Status: Acquired by Azurity (2021)

Organization Overview

First Clinical Trial
2012
NCT01587313
First Marketed Drug
2006
erythromycin (ilosone)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Arbor Pharmaceuticals | Arbor Pharmaceuticals, Inc. | Arbor Pharmaceuticals, LLC | Arbor Pharmaceuticals, LLC. | ARBOR PHARMS INC | ARBOR PHARMS LLC

Active Ingredients

Marketed Drugs (14)

Key: Arbor Pharmaceuticals (13) Acquired (1)

acetylcysteine (mucomyst) (2016)

amphetamine (Adderall) (2012)

azilsartan (edarbi) (2011)

carmustine (bicnu) (1996)

chlorthalidone (Hygroton) (2011)

dextroamphetamine (Dexedrine) (2011)

erythromycin (ilosone) (1970)

gabapentin (neurontin) (2011)

hydralazine (apresoline) (2005)

isosorbide (isordil) (2005)

ivermectin (stromectol) (2012)

nimodipine (nimotop) (2013)

sotalol (betapace) (2014)

triptorelin (Trelstar) (2017)

Drugs in Phase 4 Trials (2)

Key: Arbor Pharmaceuticals (1) Acquired (1)

amphetamine (Adderall) (2 trials)

gabapentin (neurontin) (21 trials)

Drugs in Phase 3 Trials (4)

azilsartan (edarbi) (1 trial)

benzocaine (Orajel) (3 trials)

glycerin (1 trial)

losartan (cozaar) (1 trial)

Drugs in Phase 2 Trials (15)

Key: Arbor Pharmaceuticals (2) Acquired (13)

ar08 (2 trials)

arbaclofen (4 trials)

carbidopa (sinemet) (2 trials)

carmustine (bicnu) (1 trial)

diphenhydramine (benadryl) (2 trials)

dopamine (intropin) (2 trials)

esomeprazole (nexium) (1 trial)

lansoprazole (prevacid) (1 trial)

omeprazole (prilosec) (1 trial)

pantoprazole (protonix) (1 trial)

pregabalin (lyrica) (1 trial)

rabeprazole (pariet) (1 trial)

sodium bicarbonate (1 trial)

xp21279 (2 trials)

xp23829 (1 trial)

Drugs in Phase 1 Trials (6)

Key: Arbor Pharmaceuticals (4) Acquired (2)

acetylcysteine (mucomyst) (1 trial)

ar09 (1 trial)

hydralazine (apresoline) (2 trials)

isosorbide (isordil) (2 trials)

morphine (1 trial)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 4)

Brain Diseases (Phase 2)

Heart Failure (Phase 1)

Hyperkinesis (Phase 4)

Hypertension (Phase 3)

Otitis (Phase 3)

Otitis Media (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial APIs: 27